Clinical trial
Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid…
NCT00070239 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00070239 |
|---|---|
| Title | Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies |
| Official title | A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other, Procedure, Radiation |
| Interventions | alvocidib, pharmacological study, fludeoxyglucose F 18, fluorine F 18 fluorothymidine, positron emission tomography |
| Enrollment | 100 |
| Start date | Aug 1, 2003 |
| Primary completion | Jun 1, 2006 |
| First posted | Oct 7, 2003 |
| Last update posted | Dec 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: